Cidara Theraptcs Stock Price, News & Analysis

Cidara Therapeutics (NASDAQ: CDTX) announced presentations of clinical data on rezafungin at the ISHAM Asia Congress from August 6-8, 2021. Rezafungin, a novel once-weekly echinocandin, aims to treat and prevent serious fungal infections. The presentations will include updated findings from the Phase 2 STRIVE study and activity analysis against Candida and Aspergillus spp. isolates from Asia-Pacific. The Chief Medical Officer, Taylor Sandison, will lead these discussions, showcasing the progress of the ongoing Phase 3 trials.

Cidara Therapeutics (NASDAQ: CDTX) presented new clinical data on rezafungin at the ECCMID 2021, showcasing its effectiveness in treating candidemia. The oral presentation highlighted that a single dose of rezafungin significantly improved infection clearance compared to standard treatments like caspofungin. Critical findings from the STRIVE Phase 2 trial indicated higher rates of negative blood cultures within 24 and 48 hours for patients treated with rezafungin. The ongoing Phase 3 ReSTORE trial aims to validate these results, with top-line data expected by the end of 2021.

Cidara Therapeutics (Nasdaq: CDTX) announced the grant of 172,000 stock options and restricted stock units to eight new employees under its 2020 Inducement Incentive Plan. The options have an exercise price of $2.02 per share, equivalent to the stock's closing price on June 30, 2021. Vesting occurs over four years, with 25% vesting after one year and the remainder in equal monthly installments. These awards are a strategic inducement to attract new talent in line with Nasdaq rules.

Cidara Therapeutics, Inc. (NASDAQ: CDTX) announced the resignation of CFO James Levine, effective July 9, 2021, to pursue new opportunities. Levine will continue to provide consulting support for at least six months. CEO Jeffrey Stein praised Levine for his leadership and contributions to partnerships with Mundipharma and Janssen Pharmaceuticals. In light of this change, Stein will also take on the role of principal financial officer, while Brady Johnson has been promoted to vice president of finance and principal accounting officer, enhancing the company's financial management.

Cidara Therapeutics (NASDAQ: CDTX) is set to present new analyses, including an oral presentation on rezafungin, at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) virtually from July 9-12, 2021. Rezafungin, a once-weekly echinocandin, is currently in Phase 3 trials for treating serious fungal infections in critically ill patients. Highlights include a session on the STRIVE Phase 2 trial's efficacy and safety analysis. The presentations will be accessible via Cidara's website and ECCMID's platform.

Cidara Therapeutics (Nasdaq: CDTX) announced that CEO Jeffrey Stein and CFO James Levine will participate in investor meetings at the Raymond James Human Health Innovation Conference from June 21-23, 2021. The company focuses on developing long-acting therapeutics to address serious fungal and viral infections, with notable products including the antifungal candidate rezafungin and antiviral candidates from its Cloudbreak platform. Cidara is headquartered in San Diego, California.

Cidara Therapeutics (NASDAQ: CDTX) announced its participation in the Mycology 2021 Conference, showcasing results from pre-clinical to Phase 2 trials of rezafungin, a novel, once-weekly echinocandin for invasive fungal disease treatment and prevention. The spotlight presentation will occur on June 12, 2021, featuring Dr. Varun Mehra from Kings College Hospital. Rezafungin aims to enhance safety and efficacy in treating serious fungal infections, currently in Phase 3 trials: ReSTORE for candidemia and ReSPECT for prevention in allogeneic transplant patients.

Cidara Therapeutics (Nasdaq: CDTX) reported Q1 2021 financial results with revenue at $2.4 million, a slight decrease from $2.5 million in Q1 2020. The net loss widened to $18.3 million from $14.5 million year-over-year. Cidara secured a worldwide licensing agreement with Janssen for its Cloudbreak influenza AVCs, bringing an upfront payment of $27 million and potential total funding of $753 million. R&D expenses increased to $15.8 million, influenced by ongoing rezafungin trials and antiviral platform costs. Cidara remains focused on advancing its product pipeline and anticipates key developments by year-end.

Cidara Therapeutics (Nasdaq: CDTX) is set to present at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 1:30 PM ET. CEO Jeffrey Stein will provide a corporate overview highlighting the company’s commitment to developing long-acting therapeutics for severe fungal and viral infections. Cidara's lead candidate is rezafungin, part of its innovative Cloudbreak® antiviral platform. Investors can access the live audio webcast on the company’s website.